Skip to NavigationSkip to content

GSK's Zejula meets primary endpoint in Phase 3 trial of patients with ovarian cancer

Published on 15/07/19 at 10:09am

British multinational GlaxoSmithKline has said ovarian cancer drug Zejula (niraparib) met its primary endpoint in a Phase 3 trial.

Zejula showed a statistically significant improvement in progression free survival in women with first-line ovarian cancer who had undergone platinum-based chemotherapy regardless of their biomarker status. The safety and tolerability of the drug was consistent with previous clinical trials.

GSK gained the rights to Zejula, an orally active small molecule PARP inhibitor, after acquiring the Massachusetts-based firm Tesaro for $5.1 billion in 2018. PARP inhibitors work by blocking enzymes involved in repairing damaged DNA.

Dr Hal Barron, Chief Scientific Officer and President, R&D, GSK, commented: “Almost 300,000 women around the world are diagnosed with ovarian cancer every year, yet only about 15% of patients are currently eligible to receive PARP inhibitors as their initial therapy. These exciting data demonstrate that ZEJULA has the potential to significantly benefit even more women with this devastating cancer.”

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches